Clinical Trials
204 trialsTRIDENT-1
Turning Point Therapeutics, Inc.
PIKALO-1
Eli Lilly and Company
INDIGO
Boston Scientific Corporation
SUNRAY-01
Eli Lilly and Company
FOREFRONT
AstraZeneca
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
M.D. Anderson Cancer Center
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
Revolution Medicines, Inc.
LADOGA
AstraZeneca
GRECCAR 5
University Hospital, Bordeaux
CISTO
University of Washington
EV-309
Astellas Pharma Inc
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
APEX
Cogent Biosciences, Inc.
Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer
Endocyte
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
ROWAN
Boston Scientific Corporation
Real World Registry for Use of the Ion Endoluminal System
Intuitive Surgical
P300
Pathos AI, Inc.
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Revolution Medicines, Inc.
SERENA-6
AstraZeneca
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
Pfizer
LIBRETTO-001
Eli Lilly and Company
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Orca Biosystems, Inc.
Savolitinib vs. Sunitinib in MET-driven PRCC.
AstraZeneca
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Corcept Therapeutics
ENGOT-EN5
Karyopharm Therapeutics Inc
An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors
Bristol-Myers Squibb
ELECTRA
Stemline Therapeutics, Inc.
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Cedars-Sinai Medical Center
STRIKE-001
K36 Therapeutics, Inc.
REVIVE
AstraZeneca
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
AcceleRET-Lung
Hoffmann-La Roche
LOTOS
AstraZeneca
HORIZONS
Massachusetts General Hospital
DETERMINE
Cancer Research UK
VALOR
VA Office of Research and Development
Research Development13(RD13)-02 Cell Injection in Patients With Relapsed or Refractory Cluster Of Differentiation 7(CD7)-Positive Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Small/Middle Tier Cities and County Lung Cancer Quality Improvement Project (QIP) Study
AstraZeneca
OPTICS
DL Analytics
LIBRETTO-121
Eli Lilly and Company
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
QoLATI
Rigshospitalet, Denmark
Tale EAP
Nuvation Bio Inc.
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
TELESCOPE-H
Rutgers, The State University of New Jersey
DETERMINE
Cancer Research UK
DETERMINE
Cancer Research UK